AAN-14x

N/A

Report date: 2026/05/12 09:17:05

Base Information

Drug NameAAN-14x

Drug Alias NameAAN-14xAAN14x

ClassificationCell and gene therapy > Gene therapy > mRNACell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapy

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsAutoimmune DiseasesHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAanastra Inc

China Registration ClassN/A

Develop Information

Active CompaniesAanastra Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune DiseasesHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A